Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Biocon Ltd dropped for a fifth straight session today. The stock is quoting at Rs 346.3, down 1.06% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 1.19% on the day, quoting at 22497.45. The Sensex is at 72413.6, up 1.15%.Biocon Ltd has lost around 11.58% in last one month.Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has eased around 2.39% in last one month and is currently quoting at 25823.25, up 0.38% on the day. The volume in the stock stood at 9.66 lakh shares today, compared to the daily average of 31.2 lakh shares in last one month.
The benchmark October futures contract for the stock is quoting at Rs 348.55, down 0.19% on the day. Biocon Ltd tumbled 2.02% in last one year as compared to a 11.03% slide in NIFTY and a 16.66% spurt in the Nifty Pharma index.
The PE of the stock is 188.65 based on TTM earnings ending June 26.
In July, Biocon had secured regulatory approval from the European Medicines Agency (EMA) for this new drug product fill-finish line.
The announcement was made before market hours today, 25 September 2026.
Biocon is a Bengaluru-based biopharmaceutical company focused on biosimilars and generic medicines, with operations across more than 120 countries.
The company had reported 355% jump in consolidated net profit to Rs 141 crore in Q1 FY27 from Rs 31 crore in Q1 FY26. Revenue from operations rose by 10% year-on-year (YoY) to Rs 4,336 crore during the period under review.
The scrip shed 0.58% to currently trade at Rs 384.75 on the BSE.
The positive opinion follows the review of a marketing authorisation application submitted by Biocon Biologics Ireland, an indirect wholly owned subsidiary of Biocon Biologics.
Biocon said its Pertuzumab biosimilar is the first monoclonal antibody biosimilar to receive a positive CHMP opinion under the EMA's tailored clinical development approach. The company said the application was supported by structural and functional analytical characterisation and comparative clinical pharmacokinetic data.
The European Commission will now conduct the final review and decide on marketing authorisation. Biocon said Pebrilzo is not authorised for use in the European Union until marketing authorisation is granted.
Pebrilzo contains Pertuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). It is indicated for use with Trastuzumab and chemotherapy in certain patients with HER2-positive early-stage or locally advanced breast cancer. It is also indicated with Trastuzumab and Docetaxel for certain patients with HER2-positive metastatic or locally recurrent unresectable breast cancer.
Biocon said comparative analytical and clinical pharmacokinetic data demonstrated high similarity between Pebrilzo and the reference biologic, with no clinically meaningful differences in quality, safety or efficacy.
Biocon Ltd gained for a third straight session today. The stock is quoting at Rs 394.4, up 2.44% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.29% on the day, quoting at 23413.6. The Sensex is at 74819.64, up 0.71%. Biocon Ltd has slipped around 3.66% in last one month.
Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 2.67% in last one month and is currently quoting at 26710.1, up 1.25% on the day. The volume in the stock stood at 22.73 lakh shares today, compared to the daily average of 32.57 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 394.85, up 2% on the day. Biocon Ltd is up 8.91% in last one year as compared to a 7.1% drop in NIFTY and a 20.91% drop in the Nifty Pharma index.
The PE of the stock is 208.11 based on TTM earnings ending June 26.
OneSource Specialty Pharma Ltd, Adani Ports & Special Economic Zone Ltd, Graphite India Ltd, DLF Ltd are among the other stocks to see a surge in volumes on BSE today, 09 September 2026.
Biocon Ltd clocked volume of 168.67 lakh shares by 10:45 IST on BSE, a 75.68 times surge over two-week average daily volume of 2.23 lakh shares. The stock gained 1.55% to Rs.398.65. Volumes stood at 1.22 lakh shares in the last session.
OneSource Specialty Pharma Ltd saw volume of 6.91 lakh shares by 10:45 IST on BSE, a 34.12 fold spurt over two-week average daily volume of 20246 shares. The stock dropped 2.59% to Rs.1,545.05. Volumes stood at 86505 shares in the last session.
Adani Ports & Special Economic Zone Ltd witnessed volume of 60.3 lakh shares by 10:45 IST on BSE, a 21.52 times surge over two-week average daily volume of 2.80 lakh shares. The stock increased 2.75% to Rs.1,755.80. Volumes stood at 3.15 lakh shares in the last session.
Graphite India Ltd witnessed volume of 15.49 lakh shares by 10:45 IST on BSE, a 17.56 times surge over two-week average daily volume of 88204 shares. The stock increased 16.60% to Rs.856.40. Volumes stood at 56869 shares in the last session.
DLF Ltd witnessed volume of 33.45 lakh shares by 10:45 IST on BSE, a 15.02 times surge over two-week average daily volume of 2.23 lakh shares. The stock dropped 1.23% to Rs.667.65. Volumes stood at 9.14 lakh shares in the last session.
Biocon announced the signing of partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil, marking an important milestone in advancing production and commercialisation of the HER2-positive breast cancer therapy under the country's Productive Development Partnership (PDP) program.
The consortium of Biocon, Bahiafarma and Bionovis received 100% allocation under Brazil's 10-year PDP program for Pertuzumab.
The PDP provides the consortium exclusive access to Brazil's public healthcare market, which accounts for approximately 70% of the country's demand for Pertuzumab. It also supports the long term adoption of Biocon's product within Brazil's public oncology network.
Biocon will receive milestone payments and a share of revenues generated from the Brazil PDP opportunity over a 10-year period. As part of the PDP framework, the product will undergo phased localization in Brazil in the mid to long term.
This agreement would mark an important milestone in advancing production and commercialisation of the HER2-positive breast cancer therapy under the country’s productive development partnership (PDP) program.
Pertuzumab is a monoclonal antibody used in the treatment of HER2-positive breast cancer. Currently, the product is not manufactured locally in Brazil and is a significant expenditure for the country's Unified Health System (SUS).
Bahiafarma is a public pharmaceutical laboratory of the State of Bahia, Brazil, focused on pharmaceutical research, technological development, innovation and the production and supply of medicines and other health products, particularly for Brazil’s SUS.
Bionovis is a Brazilian biotechnology company focused on developing, manufacturing and commercializing complex biological medicines and biosimilars, with a strong emphasis on technology transfer, local biopharmaceutical manufacturing and expanding access to advanced therapies in Brazil.
The PDP provides the consortium exclusive access to Brazil’s public healthcare market, which accounts for approximately 70% of the country’s demand for Pertuzumab. It also supports the long term adoption of Biocon’s product within Brazil’s public oncology network.
As part of the PDP framework, the product will undergo phased localization in Brazil in the mid to long term.
Biocon will receive milestone payments and a share of revenues generated from the Brazil PDP opportunity over a 10-year period.
Shreehas Tambe, CEO & managing director, Biocon, said: 'Brazil is an important country for Biocon, and our journey here reflects the transformative potential of strong partnerships in building local capabilities and expanding access to high-quality, affordable medicines.
This long-term supply contract for Pertuzumab marks a significant milestone in this journey, enabling us to reach more patients living with HER2-positive breast cancer and address an important healthcare need at scale.'
Biocon is India’s leading biopharma company. It is fully integrated and delivers biopharma solutions ranging from discovery to development and commercialisation. It has diversified revenue streams covering biosimilars, contract research, small molecules and APIs.
The scrip rose 0.99% to currently trade at Rs 397.40 on the BSE.
The product, a biosimilar to Neulasta, is developed and manufactured by Biocon Biologics, parent entity of Biocon Biologics UK PLC, with Global Regulatory Partners Japan serving as the marketing authorization holder on behalf of Biocon. Sandoz K.K. shall exclusively promote, sell, and distribute the product in Japan.
Pegfilgrastim is a prescription injection used to lower the risk of infection in people receiving strong cancer chemotherapy or those exposed to high doses of radiation.
'This approval further strengthens Biocon’s portfolio of biosimilar products in Japan and reaffirms the company’s commitment to increasing patient access to high-quality and affordable medications globally,' the company said in a statement.
The scrip shed 0.28% to currently trade at Rs 408.85 on the BSE.
Biocon's subsidiary in the United States has received supplemental U.S. Food and Drug Administration (FDA) approval for Yesintek® 45 mg/0.5 ml single-dose prefilled autoinjector and Yesintek® 90 mg/ml single-dose prefilled autoinjector.
Yesintek® was originally approved by the U.S. FDA on 29 November 2024. The Yesintek® single-dose prefilled autoinjector offers patients with another important treatment option. This new delivery format supports more tailored treatment approaches across different care settings and patient needs.
Yesintek® is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients 6 years of age and older, and moderate to severely active Crohn's disease and ulcerative colitis in adults—a range of debilitating autoimmune conditions that affects tens of thousands of Americans.
Yesintek was originally approved by the U.S. FDA on 29 November 2024.
The Yesintek single-dose prefilled autoinjector offers patients with another important treatment option. This new delivery format supports more tailored treatment approaches across different care settings and patient needs.
Yesintek is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients 6 years of age and older, and moderate to severely active Crohn’s disease and ulcerative colitis in adults—a range of debilitating autoimmune conditions that affects tens of thousands of Americans.
'This supplemental approval enhances Biocon’s comprehensive portfolio of immunology products in the United States and reaffirms the company’s commitment to improving access to affordable medicines for patients around the world,' the company said in a statement.
The scrip rose 0.30% to currently trade at Rs 413.35 on the BSE.